PPBT (Purple Biotech) Other Current Liabilities : $1.15 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Purple Biotech Other Current Liabilities?

Purple Biotech's other current liabilities for the quarter that ended in Dec. 2024 was $1.15 Mil.

Purple Biotech's quarterly other current liabilities increased from Jun. 2024 ($1.10 Mil) to Sep. 2024 ($1.56 Mil) but then declined from Sep. 2024 ($1.56 Mil) to Dec. 2024 ($1.15 Mil).

Purple Biotech's annual other current liabilities increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($2.52 Mil) but then declined from Dec. 2023 ($2.52 Mil) to Dec. 2024 ($1.15 Mil).

Purple Biotech Other Current Liabilities Historical Data

The historical data trend for Purple Biotech's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Purple Biotech Other Current Liabilities Chart

Purple Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Current Liabilities

Get a 7-Day Free Trial

2.52

1.15

Purple Biotech Quarterly Data
	Jun19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Current Liabilities	Get a 7-Day Free Trial															2.52	2.05	1.10	1.56	1.15

Purple Biotech Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Purple Biotech Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Purple Biotech's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Purple Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Purple Biotech Ltd (NAS:PPBT) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

PPBT:Israel

Address

4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104

Website

https://www.purple-biotech.com

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.